Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Chawla GK, Garg K, Kaur K, Chopra V, Suri R
Background Drug resistant tuberculosis (DR-TB), particularly multidrug resistance (MDR-TB) and extensive drug resistance (XDR-TB) pose a serious threat to public health. This study aimed to identify drug resistance in pulmonary tuberculosis patients and to see their association w…
Wahan SK, Bhargava G, Chawla V, Chawla PA
Multidrug-resistant tuberculosis continues to pose a health security risk and remains a public health emergency. Antimicrobial resistance result from treatment regimens that are both insufficient and incomplete leading to the emergence of multidrug-resistant tuberculosis, extensi…
Pedersen OS, Holmgaard FB, Mikkelsen MKD, Lange C, Sotgiu G, et al.
Introduction Historically, extensively drug-resistant tuberculosis has been notoriously difficult to treat with devasting outcomes. As we are coming to the end of an era where the 2006 extensively drug-resistant tuberculosis definitions and old treatment regimens are being replac…
Wilson M, Weston J, Mullen A, Knight T, Simpson G
… with global numbers, Australia has enjoyed relatively good tuberculosis control over the past 30 years, with an annual incidence of 5.7 per 100 000 population. Thanks to its unique geography and proximity to high-burden countries, such as Papua New Guinea (PNG), Far North Queens…
Dupont C, Chen Y, Xu Z, Roquet-Banères F, Blaise M, et al.
Mycobacterium tuberculosis , the causative agent of tuberculosis, remains a major human pathogen, and current treatment options to combat this disease are under threat because of the emergence of multidrug-resistant and extensively drug-resistant tuberculosis. High-throughput who…
Kim S, Seo H, Mahmud HA, Islam MI, Lee BE, et al.
Background Tuberculosis is a very serious infectious disease that threatens humanity, and the emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR) strains resistant to drugs suggests that new drug development is urgent. In order to develop new tuberculosis dru…
Ouyang Q, Zhang K, Lin D, Feng CG, Cai Y, et al.
Tuberculosis (TB) is still the leading killer caused by Mycobacterium tuberculosis infection. There is a clear need for new treatment strategy against TB. It has been reported that tamoxifen, known as a selective estrogen receptor modulator (SERM), exhibits antimycobacterial acti…
Mo S, Guo J, Ye T, Zhang X, Zeng J, et al.
Tuberculosis (TB), which is caused by the single pathogenic bacterium, Mycobacterium tuberculosis, is among the top 10 lethal diseases worldwide. This situation has been exacerbated by the increasing number of cases of multidrug-resistant TB (MDR-TB) and extensively drug-resistan…
Islam MI, Seo H, Kim S, Sadu VS, Lee KI, et al.
…nt (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis creates the urgency for new anti-tuberculosis drugs to improve the efficiency of current tuberculosis treatment. In the search for a new potential tuberculosis drug, we synthesized an isoindole based chemica…
Getu Diriba, Hilina Mollalign, Abyot Meaza, Melak Getu, Betselot Zerihun, et al.
… Rapid and accurate detection of extensively drug-resistant tuberculosis is crucial for effective intervention. Next-generation sequencing technologies have been recommended to rapidly and accurately detect resistance to second-line anti-TB drugs. We deployed whole-genome sequenc…
Yousra Kherabi, Ole Skouvig Pedersen, Christoph Lange, François Bénézit, Dumitru Chesov, et al.
…anization revised of definition of extensive drug-resistant tuberculosis. We aimed to determine treatment outcomes of individuals affected by extensively drug-resistant tuberculosis in Europe. **METHODS:** This observational, retrospective cohort study included patients diagnose…
Günther G, Guglielmetti L, Leu C, Lange C, van Leth F
…luate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries. Methods We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calcu…
Machmud PB, Gayatri D, Ronoatmodjo S
Background Tuberculosis and its resistance are a major global health problem in the world. The increased incidence and mortality of tuberculosis in Indonesia remain a big public health issue especially in Jakarta Province. No published studies have focused on assessing the outcom…
Song T, Li LJ, Liu JL, Geng SJ
…ected by multidrug-resistant and extensively drug-resistant tuberculosis. Patients and methods 179 patients suffering from tuberculosis treated in the Chest Hospital of Hebei from April 2010 to December 2015 were selected for the study. There were 47 cases affected by drug-resist…
Singh B, Cocker D, Ryan H, Sloan DJ
…th Organization (WHO) for treatment of multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), suggesting that it should be included in the regimen for all patients unless contraindicated. Linezolid use carries a considerable risk of toxic…
Daley CL, Caminero JA
Drug-resistant strains of Mycobacterium tuberculosis pose a major threat to global tuberculosis control. Despite the availability of curative antituberculosis therapy for nearly half a century, inappropriate and inadequate treatment of tuberculosis, as well as unchecked transmiss…
Kumar V, Neradi D, Sherry B, Gaurav A, Dhatt SS
Pott's spine is tuberculosis of spine caused due to hematogenous spread of mycobacterium from a primary focus. It constitutes about 50% of skeletal tuberculosis cases. Paradiscal type is the most common type of spinal tuberculosis. Untreated cases can lead to complications like a…
Leiwen Fu, Ke Liu, Yuxian Sun, Wei Shu, Yujia Ning, et al.
Tuberculosis remains a major global public health challenge, particularly among children. This study aims to provide a comprehensive assessment of the global, regional, and national burden of tuberculosis among children (0-14 years) using data from the Global Burden of Disease (G…
Swinkels HM, Jilani TN, Tobin EH
Tuberculosis (TB) is a preventable and, in most cases, curable disease. Nonetheless, it remains a formidable public health challenge, killing more than 1.25 million people in 2023. The world's most prevalent human infection, it has affected humans across millennia and killed more…
Kulimbet M, Yergasen A, Glushkova N, Adenov M, Davletov K
… provision of timely medical services in detecting cases of tuberculosis in the population. The aim of this study was to study the influence of COVID-19 pandemic on the tuberculosis incidence in the Republic of Kazakhstan. Methods We analyzed national data on the reported tubercu…
Ramanujam H, Refaya AK, Thiruvengadam K, Pazhanivel N, Kandasamy D, et al.
Background India has the highest global burden of human tuberculosis (TB) and the largest cattle herd with endemic bovine TB (bTB). However, the extent of cross-species transmission and the zoonotic spillover risk, including drug-resistant Mycobacterium tuberculosis complex (MTBC…
Xiao S, Guo H, Weiner WS, Maddox C, Mao C, et al.
…effectiveness of β-lactam antibiotics against Mycobacterium tuberculosis has hindered the utility of this compound class for tuberculosis treatment. However, the results of treatment with a second-line regimen containing meropenem plus a β-lactamase inhibitor were found to be enc…
Saravanan M, Niguse S, Abdulkader M, Tsegay E, Hailekiros H, et al.
Tuberculosis (TB) remains a major global health problem and ranks as the second leading cause of death among deaths caused by infectious diseases worldwide. Although the availability of short-course regimens as first-line anti-tuberculosis drugs, the emergence of drug-resistant M…
Edessa D, Adem F, Hagos B, Sisay M
… most feared public health threats that commonly challenges tuberculosis treatment success. Since 2010, there have been rapid evolution and advances to second-line anti-tuberculosis treatments (SLD). However, evidence on impacts of these advances on incidence of mortality are sca…
Li W, Deng W, Xie J
Tuberculosis, caused by Mycobacterium tuberculosis , remains a leading cause of morbidity and mortality globally, with nearly 10.4 million new cases of incidence and over 1.7 million deaths annually. Drug-resistant M. tuberculosis strains, especially multidrug-resistant or extens…